Ascendis Pharma A/S
ASND
$207.71
$7.213.59%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -71.30M | -44.10M | -99.58M | -41.01M | -109.06M |
| Total Depreciation and Amortization | 4.70M | 4.89M | 4.78M | 4.27M | 4.81M |
| Total Amortization of Deferred Charges | -- | -- | -- | 497.80K | -- |
| Total Other Non-Cash Items | 40.31M | 80.55M | 26.88M | 65.20M | -47.33M |
| Change in Net Operating Assets | 28.81M | -49.67M | 52.86M | -121.89M | 89.87M |
| Cash from Operations | 2.52M | -8.33M | -15.06M | -92.93M | -61.71M |
| Capital Expenditure | -62.00K | -4.92M | -739.80K | -446.60K | -553.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | 0.00 | 0.00 |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | 37.30K | 0.00 |
| Cash from Investing | -62.00K | -4.92M | -739.80K | -409.30K | -553.00K |
| Total Debt Issued | -- | -- | -- | 0.00 | 134.16M |
| Total Debt Repaid | -6.57M | -5.49M | -3.07M | -2.95M | -2.81M |
| Issuance of Common Stock | 45.43M | 12.47M | 13.83M | 22.33M | 296.53M |
| Repurchase of Common Stock | 0.00 | 0.00 | -28.79M | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -19.29M | -- |
| Cash from Financing | 45.42M | 7.92M | -18.97M | 92.70K | 470.39M |
| Foreign Exchange rate Adjustments | 4.78M | -21.77M | -9.03M | 22.92M | -4.86M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 52.66M | -27.10M | -43.80M | -70.32M | 403.27M |